AUCTORES
Globalize your Research
Case report | DOI: https://doi.org/10.31579/2578-8868/307
1M4 student Virginia Commonwealth University School of Medicine.2Department of Neurology, Virginia Commonwealth University Health System 11958 W. Broad Street, 4th floor, Henrico, VA 23233, USA.
*Corresponding Author: Xinli Du, MD PhD Department of Neurology, Virginia Commonwealth University Health System 11958 W. Broad Street, 4th floor, Henrico, VA 23233, USA.
Citation: Huang He Ding, Xinli Du, (2024), Rituximab in the Treatment of LRP4-Antibody-Positive Myasthenia Gravis: A Case Report, J. Neuroscience and Neurological Surgery, 14(2); DOI:10.31579/2578-8868/307
Copyright: © 2024, Xinli Du. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Received: 29 February 2024 | Accepted: 15 March 2024 | Published: 26 March 2024
Keywords: myasthenia gravis; lrp4 autoantibody; rituximab; efficacy
Antibodies against LRP4 were found in 2-4% of patients with myasthenia gravis (MG). LRP4-antibody-positive (LRP4+) MG presents with more severe disease with bulbar involvement. No standard treatment guideline has been established for this subtype. We identified a LRP4+MG patient with severe symptoms including bulbar dysfunction that were refractory to standard therapy. Rituximab was started due to treatment failure with standard therapy. At the time of initiation of rituximab, patient was on plasmapheresis every 1-2 weeks. Her work and quality of life were greatly compromised. Six weeks after initiating rituximab therapy, remarkable improvements in dyspnea, dysphagia, ptosis, and proximal limb muscle strength were reported without adverse events. Improvements in 3 standardized Myasthenia Gravis scoring systems were observed. The maintenance plasmapheresis was discontinued and pyridostigmine dose decreased by 50% because of sufficient symptom control. Stable improvement was achieved with rituximab maintenance therapy spaced 5 months apart. Our case demonstrates rapid onset of efficacy of rituximab in patient with refractory LRP4+MG. This response and the proposed mechanism of action of LPR4-Ab suggest that the efficacy of rituximab in LRP4+MG may parallel that in MuSK+MG. Further exploration of this treatment option is warranted.
Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder affecting the neuromuscular junction (NMJ) function leading to fluctuating weakness of ocular, facial, bulbar, limb and respiratory muscles.[1] Approximately 80% of patients with generalized MG have antibodies targeting the acetylcholine receptors (AChR), and about 10% have antibodies against the muscle specific kinase (MuSK) protein.[2] Among the remaining seronegative MG patients, about 15% have antibodies recognizing lipoprotein-related protein 4 (LRP4) and/or agrin.[3] Although majority of MG patients respond to standard therapies including cholinesterase inhibitors, corticosteroids, steroid-sparing immunosuppressants such as mycophenolate mofetil and azathioprine, up to 15% patients still experience insufficient control of symptoms or intolerable side effects.[4,5] Identification of MG autoantibodies is a key step, as it not only helps with confirming diagnosis but also guides management of MG. For example, complement inhibitors are indicated only for AChR+MG based on the finding that complement activation and subsequent destruction of postsynaptic membrane by the membrane attack complex play a critical role in pathogenesis of AChR+MG;[6,7,8] thymectomy is effective in young AChR+MG but not in MuSK+MG as thymic hyperplasia rarely occurs in MuSK+MG;[10] rituximab is highly efficacious in MuSK+MG.[9]
LRP4 autoantibodies are believed to be pathogenic for MG by disrupting activation of MuSK.[11] LRP4+MG patients tend to report more severe disease with increased bulbar involvement similar to MuSK+MG patients. LRP4+MG patients are oftentimes managed with standard therapy due to lack of studies on effective treatment regimen.[3] We report a case of LRP4+MG patient with a refractory disease course who had excellent response to rituximab.
The patient presented in this case is a 54-year-old Caucasian female with relevant past medical history of depression, recurrent pulmonary infections (on chronic prophylactic antibiotics). She presented in her late 20s with muscle fatigue, ptosis, and dyspnea followed by dysphagia, at one point requiring parenteral feeding. Her initial work up included normal routine EMG, normal repetitive nerve stimulation studies, and negative AChR and MuSK autoantibodies. Her initial single fiber EMG (SFEMG) was nondiagnostic due to poor cooperation. She was empirically diagnosed with MG based on her clinical presentation and treatment response to pyridostigmine. Her MG symptoms worsened shortly after the diagnosis that led to multiple admissions for MG crisis and required chronic non-invasive ventilation at night and short periods during the day due to insufficiently controlled dyspnea and de-saturation. Prednisone offered some benefits but caused severe depression and avascular necrosis in the right hip. She received IVIG every 2-4 weeks for ~3 years and was switched to plasmapheresis (PLEX) due to frequent worsening of MG symptoms leading to numerous admissions for respiratory failure. Due to her history of recurrent pulmonary infection, her pulmonologist was resistant to chronic immunosuppression. She continued PLEX for 6 years; initial frequency every 3 weeks, increased to every 1-2 weeks due to insufficient control of bulbar symptoms. She continued to have frequent ED visits and admissions due to episodic worsening of MG symptoms. Repeat SFEMG of the extensor digitorum communis 2weeks following PLEX demonstrated increased jitter in 3/20 pairs with evidence of blocking. LRP4 antibody was subsequently checked and found to be positive for 2 times. Rituximab at 1000mg spaced by 14 days were initiated after consultation with her pulmonologist. The patient tolerated the infusion well. Six weeks after rituximab infusion, she noted significant improvement in dyspnea, dysphagia, ptosis, and proximal limb muscle strength. Plasmapheresis was tapered off and the daytime pyridostigmine dose was decreased by 50%. Evaluation at 11 weeks post initiation of rituximab infusion demonstrated 11-point improvement in the Myasthenia Gravis Activities of Daily Living profile (MG-ADL), 4-point improvement in Myasthenia Gravis Quality-of-Life 15 scale (MG-QoL15r), and 11-point improvement in Myasthenia Gravis Composite scale (MSC) (Fig 1). She no longer needed respiratory support during the day and reported greater tolerance of physical activities. She was exacerbation-free for 4.5 months, at which point rituximab therapy was repeated with similar clinical response. She had no pulmonary infections since initiating rituximab.
Figure 1: MGC, MG-ADL 15, MG ADL scores before and after Rituximab infusion.
The identification of antibodies is a key step in the workup of myasthenia gravis, as it not only confirms the diagnosis and can dictate the appropriate treatment. Common therapeutic options such as early referral for thymectomy should be considered for AChR+MG in patients younger than the age of 50, while newer therapeutics such as complement inhibitors and FcRn antagonists are indicated only for AChR+MG.[5,10] The International Consensus Guidance for Management of Myasthenia Gravis 2020 update recommends rituximab be considered as an early therapeutic option in patients with MuSK+MG who have an unsatisfactory response to initial immunotherapy, while in refractory AChR+MG, the efficacy of rituximab is uncertain and only be considered if patients fail or do not tolerate other immunosuppressant agents.[12]
LRP4+MG is a rare subtype of MG. It is believed that LRP4 interacts with agrin and MuSK to activate the kinase and initiates downstream signaling cascades for AChR clustering.[13] Recent work in mice has demonstrated that the presence of anti-LRP4/agrin antibodies in MG patients are pathogenic through disruption of agrin-dependent LRP4-MuSK interaction.[11]
No established treatment guidelines exist for LRP4+MG and there are few published reports of effective treatments. One multicenter case series study has demonstrated that patients with LRP4 antibodies experience more severe symptoms than those with double seronegative MG, and that LRP4+MG are generally managed with conventional immunosuppressant therapy.[3] The study also had 11% of its participants undergone treatment with rituximab, although the treatment response was not specified.[3] Our case demonstrates rapid onset of efficacy along with persistent action for a duration of 4.5 months in a patient with refractory LRP4+MG following rituximab infusion. Similar benefits were observed with maintenance infusion every 5 months.
Considering the pathophysiologic mechanism of LRP4 and its close interaction with the MuSK protein, the efficacy of selective B-cell depletion agents such as rituximab in LRP4+MG may be similar to that in MuSK+MG.[3,13] As a case report, extrapolation of this single data point is not feasible. Being a small subset of a rare disease, enrolment of enough patients to detect a significant therapeutic response is challenging. Many recent clinical trials of promising new MG therapies exclude sero-negative and LRP4+ patients, regardless of the potential efficacy. Publication of case reports of effective treatments in this population will help direct the development of a much-needed data-driven targeted algorithm for managing LRP4+MG.
Treatment for myasthenia gravis is rapidly evolving owing to the advance in identification of autoantibodies, understanding of the pathogenesis both at the neuromuscular junction and broadly the immune system, and the development of targeted therapeutics. Most of the new therapies are for AChR+MG. LRP4+MG represents a small portion but tends to have more severe clinical symptoms including bulbar dysfunction that can be refractory to standard therapies developed for AChR+MG. Guidelines and evidence-based practice specific for LRP4+MG are missing, as a result, obtaining approval for using non-standard therapy in patients with LRP4 antibody can be challenging. Our case report showed that rituximab had fast onset and persistent benefits in a LRP4+MG patient with severe and refractory disease. This opens the door for future research study of the efficacy of rituximab either by large case series or randomised control trial.
Both authors have no disclosure
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
